Haematologica

Article	Citations
Pediatric acute lymphoblastic leukemia	259
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy	194
International recommendations on the diagnosis and treatment of acquired hemophilia A	176
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia	97
Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia	93
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma	89
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors	88
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial	84
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens	76
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	74
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma	74
Multiple myeloma: the (r)evolution of current therapy and a glance into future	71
Acquired von Willebrand syndrome: focused for hematologists	70
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models	70
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion	64
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide	63
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition	62
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study	61
History of hematopoietic cell transplantation: challenges and progress	60
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study	58
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT	58
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE t	57
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria	55
Geriatric assessment in older patients with a hematologic malignancy: a systematic review	55
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis	53

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia	51
Complement C5 inhibition in patients with COVID-19 - a promising target?	50
Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies	50
A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies	48
Myelodysplastic syndromes: moving towards personalized management	48
Post-mortem findings in vaccine-induced thrombotic thombocytopenia	47
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients	47
ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults	46
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma	46
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies	46
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma	44
VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome)	44
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma	44
Targeting the tumor microenvironment in chronic lymphocytic leukemia	43
Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance	43
Inherited thrombocytopenias: history, advances and perspectives	43
Potential targeting of FLT3 acute myeloid leukemia	43
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913	43
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression	43
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk	42
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome	42
The interactome of the N-terminus of band 3 regulates red blood cell metabolism and storage quality	41
miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis	41
Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS	40
Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients	39
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells	38
Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy	37
Red cell transfusion and alloimmunization in sickle cell disease	37
Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?	37
Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany	37
<i>In vitro</i> and <i>in vivo</i> induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor	35
Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial	35
A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis	35
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome	34
Leukemic stem cells and therapy resistance in acute myeloid leukemia	34
<i>DUX4r</i>, <i>ZNF384r</i> and <i>PAX5</i>-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch	34
Complement dysregulation is associated with severe COVID-19 illness	34
Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood s	33
A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol	33
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies	33
Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York	33
Multiple myeloma with central nervous system relapse	33
Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines	33
The molecular basis for the prothrombotic state in sickle cell disease	33
Unique ethnic features of <I>DDX41</I> mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia	32
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas	32
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation	31
Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis	31
No evidence of hemoglobin damage by SARS-CoV-2 infection	31
Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemia	31

Molecular heterogeneity of pyruvate kinase deficiency	30
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape	30
Hemostatic alterations in COVID-19	29
IgM monoclonal gammopathies of clinical significance: diagnosis and management	29
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma	29
The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia	29
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia	29
The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy	28
Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma	28
Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy	28
Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding	28
COVID-19 and sickle cell disease	28
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia	28
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?	27
Molecular and phenotypic diversity of <I>CBL</I>-mutated juvenile myelomonocytic leukemia	27
COVID-19 in patients with sickle cell disease - a case series from a UK Tertiary Hospital	27
Circulating histones play a central role in COVID-19-associated coagulopathy and mortality	27
The clinical impact of the molecular landscape of acute myeloid leukemia	27
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma	27
The variable manifestations of disease in pyruvate kinase deficiency and their management	27
Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease	26
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leuke	26
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter	26
Successful pregnancies after transplantation of ovarian tissue retrieved and cryopreserved at time of childhood acute lymphoblastic leukemia – A case report	25
Mortality in children with sickle cell disease in mainland France from 2000 to 2015	25
Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia	25
Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways	25
Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect	25
Beta thalassemia minor is a beneficial determinant of red blood cell storage lesion	24
Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome	24
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study	24
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis	24
Endothelial damage and dysfunction in acute graft-versus-host disease	24
Dramatic presentation of acquired thombotic thrombocytopenic purpura associated with COVID-19	24
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study	23
Stored blood has compromised oxygen unloading kinetics that can be normalized with rejuvenation and predicted from corpuscular side-scatter	23
BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy	23
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome	23
Ddx41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish	23
Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies	23
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute l	23
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study	23
Aging of human hematopoietic stem cells is linked to changes in Cdc42 activity	22
The present and future of measurable residual disease testing in acute myeloid leukemia	22
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study	22
Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma	22
Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease	22
Novel immunotherapies in multiple myeloma – chances and challenges	22
Treatment of drug-induced immune thrombocytopenias	22
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde	22
Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies	22
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study	21
Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia	21
Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies	21
XPO1 regulates erythroid differentiation and is a new target for the treatment of β-thalassemia	21
Marginal zone lymphoma: present status and future perspectives	21
CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients	21
A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia	21
CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity	20
Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations	20
Comparison of CD38 antibodies <i>in vitro</i> and <i>ex vivo</i> mechanisms of action in multiple myeloma	20
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study	20
Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease	20
Deregulation of JAK2 signaling underlies primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T-cell lymphoma	20
Translational and clinical advances in acute graft-versus-host disease	20
<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)	20
Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma	20
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag	19
Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis	19
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia	19
Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype	19
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma	19
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia	19
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades	19
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model	19
Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents	18
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients	18
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas	18
The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis	18
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results	18

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis	18
The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma	18
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies	18
Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets	18
T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective	18
Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab	18
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration	18
The TRPV2 channel mediates Ca2+ influx and the Δ9-THC-dependent decrease in osmotic fragility in red blood cells	18
Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination	17
PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia	17
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study	17
Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation	17
Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis	17
Prevention and management of secondary central nervous system lymphoma	17
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia	17
Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing	17
Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment	17
Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing	17
Glenzocimab does not impact glycoprotein VI-dependent inflammatory hemostasis	17
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies	17
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc</i> expert panel	17
Towards manufactured red blood cells for the treatment of inherited anemia	17
Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse	16
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial	16
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study	16
Protein-L-isoaspartate O-methyltransferase is required for <i>in vivo</i> control of oxidative damage in red blood cells	16
Perforin gene variant A91V in young patients with severe COVID-19.	16
The Hsp70 chaperone system: distinct roles in erythrocyte formation and maintenance	16
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis	16
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation	16
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib	16
Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.	16
A frequent nonsense mutation in exon 1 across certain HLA-A and -B alleles in leukocytes of patients with acquired aplastic anemia	16
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome	16
Baseline SUV<sub>max</sub> is related to tumor cell proliferation and patient outcome in follicular lymphoma	16
The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial	16
Dominance of an <i>UBA1</i> mutant clone over a <i>CALR</i> mutant clone: from essential thrombocytemia to VEXAS.	16
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities	15
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients	15
Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis- related graft failure and disseminated bacillus Calmette-Guérin infection	15
Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature	15
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)	15
Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia	15
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis	15
Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine	15
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications	15
Crucial role of hematopoietic <i>JAK2</i> V617F in the development of aortic aneurysms	15
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06	15
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential	15
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia	15
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project	15
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients	15
Circulating cell-free <i>BRAF</i> V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis	15
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients	15
Differentiation therapy of myeloid leukemia: four decades of development	15
Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia	15
Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia	14
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome	14
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia	14
Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes	14
Post-translational polymodification of β1-tubulin regulates motor protein localization in platelet production and function	14
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial	14
SARS-CoV-2 infection in aplastic anemia	14
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma	14
Acute myeloid leukemia shapes the bone marrow stromal niche <i>in vivo</i>	14
Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy	14
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial	14
A novel classification of hematologic conditions in patients with Fanconi anemia	14
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications	14
Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia	14
New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia	14
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?	14
Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial	14
<i>DUSP22</i> rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma	13
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study	13
Mobilization efficiency is critically regulated by fat via marrow PPARδ	13
GNE-related thrombocytopenia: evidence for a mutational hotspot in the ADP/substrate domain of the GNE bifunctional enzyme	13
The “7+3” regimen in acute myeloid leukemia	13
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study	13
The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias	13
Mitochondrial ATP generation in stimulated platelets is essential for granule secretion but dispensable for aggregation and procoagulant activity	13
Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?	13
Prospects in the management of patients with follicular lymphoma beyond first-line therapy	13
Time for an individualized approach to first-line management of follicular lymphoma	13
Untargeted metabolic profiling in dried blood spots identifies disease fingerprint for pyruvate kinase deficiency	13
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia	13
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma	13
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study	13
How I diagnose and treat chronic myelomonocytic leukemia	13
Hypoxia-inducible erythropoietin expression: details matter	13
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i>-rearranged acute	13
Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial	13
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma	13
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia	13
A risk score based on real-world data to predict early death in acute promyelocytic leukemia	13